Cerebral Palsy stem cell therapy — your questions answered (2026)
About stem cell therapy for Cerebral Palsy
Cerebral palsy describes permanent disorders of movement and posture caused by disturbance in the developing brain; needs and associated conditions vary widely. Cell research has explored cord-blood and other products as possible modulators of inflammation or plasticity, usually alongside rehabilitation. These hypotheses do not mean that established brain injury is reversed or that different cell sources are equivalent.
The evidence for Cerebral Palsy
Studies must separate the cell intervention from maturation, intensive rehabilitation, expectation and assessor bias. Results should be interpreted by product, dose, route, cerebral-palsy subtype, age, comparator and validated functional outcome, with complete adverse-event reporting. The FDA regenerative-medicine patient page does not identify an approved regenerative therapy for cerebral palsy; verify any proposed study with the regulator and a paediatric rehabilitation team.
Keep research-product costs separate from rehabilitation, travel, accommodation, companion care and management of complications. A sponsor may cover some protocol procedures but not ordinary care. Protect funding for established therapy, equipment, education and family support.
Does stem cell therapy help cerebral palsy?
Cell therapy for Cerebral Palsy may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.
Best age for treatment?
Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.
How many infusions?
Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.
EU cost for CP?
The partner-published indicative range for an Cerebral Palsy programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for Cerebral Palsy (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗
- Clinic perspective — Stem Plus on Cerebral Palsy ↗